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Abstract
One of the events associated with Alzheimer’s disease is the dysregulation of a- versus b-cleavage of the amyloid precursor
protein (APP). The product of a-cleavage (sAPPa) has neuroprotective properties, while Ab1-42 peptide, a product of b-
cleavage, is neurotoxic. Dimerization of APP has been shown to influence the relative rate of a- and b- cleavage of APP. Thus
finding compounds that interfere with dimerization of the APP ectodomain and increase the a-cleavage of APP could lead
to the development of new therapies for Alzheimer’s disease. Examining the intrinsic fluorescence of a fragment of the
ectodomain of APP, which dimerizes through the E2 and Ab-cognate domains, revealed significant changes in the
fluorescence of the fragment upon binding of Ab oligomers—which bind to dimers of the ectodomain— and Ab
fragments—which destabilize dimers of the ectodomain. This technique was extended to show that RERMS-containing
peptides (APP695 328–332), disulfiram, and sulfiram also inhibit dimerization of the ectodomain fragment. This activity was
confirmed with small angle x-ray scattering. Analysis of the activity of disulfiram and sulfiram in an AlphaLISA assay
indicated that both compounds significantly enhance the production of sAPPa by 7W-CHO and B103 neuroblastoma cells.
These observations demonstrate that there is a class of compounds that modulates the conformation of the APP
ectodomain and influences the ratio of a-t ob-cleavage of APP. These compounds provide a rationale for the development
of a new class of therapeutics for Alzheimer’s disease.
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Introduction
Alzheimer’s disease (AD) affects more than five million people in
the US, yet it is currently without any truly effective treatment.
Although interest has in the past focused primarily on amyloid-b
(Ab), both soluble and plaque-associated, previous research from
our laboratory and others has shown that, at least in transgenic
mouse models of AD, high levels of Ab and plaque formation do
not necessarily lead to the Alzheimer’s phenotype [1]. Instead,
both pre-plaque pathophysiology—possibly due to APP signaling
and including Ab oligomers [2,3,4] —and distinct, plaque-related
pathology appear to be involved.
A number of previous reports have demonstrated toxicity of Ab
based on chemical and physical effects on the cell, such as
lysosomatropic detergent-like effects [5], metal binding [6],
generation of reactive oxygen species [7], and inhibition of LTP
[8]. Recent, complementary results argue that signaling events,
some of which are mediated by the amyloid precursor protein
(APP) itself, also play a crucial role in the development of the AD
phenotype [2,9,10,11,12,13]. Furthermore, APP has recently been
shown to be a receptor for netrin-1 [13], an axon guidance and
survival factor and to give rise to N-APP, a ligand for DR6 (death
receptor 6) [14]. In addition, binding of the multimeric APP to Ab
oligomers has recently been shown to promote the proteolytic
processing of APP and increase the production of the toxic Ab and
C-31 peptides [15]. Thus, APP may mediate either trophic, anti-
apoptotic events—when bound, for example, by netrin-1—or anti-
trophic, pro-apoptotic events—when bound, for example, by Ab
[15,16,17]. Ab-binding to APP is not well understood at the
structural level. We have recently shown that Ab oligomers bind to
parallel dimers of purified APP ectodomain and effect a distinct
conformational change—movement of the E1 domain away from
the E2 domain—that can be detected by small angle x-ray
scattering (SAXS); conversely, Ab dimers bind to parallel dimers
of APP ectodomain and split the APP ectodomain homodimer, as
well as opening the compact amino-terminal structure (‘‘popping
the top’’) of the APP ectodomain [18].
These changes in conformation may be important in setting the
balance between a-cleavage and b-cleavage of APP because the
relative rates of these cleavages are known to be affected by
interactions between APP and a number of proteins, both at the
cell surface and during recycling of APP [19,20]. Altering the
balance of these two cleavages to favor a-cleavage is of potential
therapeutic benefit for Alzheimer’s disease since it would reduce
Ab production and enhance sAPPa production, without inhibition
of the beta and gamma secretases. A precedent exists for this effect
in that an increased level of sAPPa, which contains almost the
entire ectodomain, has been shown to inhibit APP dimerization
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through the E1 domain or the Ab-cognate region with engineered
disulfides has been shown to increase Ab production, while forced
dimerization through the transmembrane domain or the C-
terminal domain [22,23] can reduce Ab production. These results
suggest that the conformation of APP in the dimer and the
mechanism of dimerization may play an important role in APP
processing. Since APP is regulated through interactions with a
number of different proteins, forcing dimerization may expose
specific binding sites within the APP ectodomain and thereby
influence its ultimate fate.
Models of APP dimerization have been proposed based on the
dimerization properties of truncation fragments or APP proteins
overexpressed with deleted domains in which the E1 domain plays
a major role [24]. Purified fragments containing either the E1
domain or its subdomains or the E2 have also been shown to
dimerize with and without disulfide cross-links, suggesting that
there may be multiple ways for APP fragments to dimerize given
sufficient concentration [25,26,27]. However, sAPPa, which
contains both the E1 and E2 domains, is a monomer in solution
and requires the presence of heparin to dimerize or form
heterocomplexes with APP [21,24,28]. In contrast, fragments of
the APP ectodomain containing the last nine residues of the APP
ectodomain (residues 615–624) that are not found in sAPPa form
parallel dimers through the E2 domain and Ab-cognate region
independent of the presence of the E1 domain, suggesting that the
E2 domain and the Ab-cognate region may play important roles in
stabilizing dimers of the full-length APP [18]. The inconsistency
between the different models of APP dimers may lie in the biology
of APP in that the APP molecules are anchored on the cell surface
through their transmembrane domains; therefore, APP molecules
on the same cell are restricted to a parallel orientation, while
sAPPa and the other ectodomain fragments are free to bind in
both parallel and anti-parallel orientations.
The location of the two potential dimer interfaces of the purified
ectodomain of APP are particularly interesting because these
locations are close to the a- and b- cleavage sites and one of the
major heparin-binding sites [29]. Compounds that disrupt these
dimerization interfaces might be able to alter the conformation of
the ectodomain sufficiently to alter the conformation of APP
adjacent to the a- and b- cleavage sites (and therefore alter the
balance of a- and b- cleavage directly), interfere with the
formation of heterodimers of APP, or interfere with dimerization
of APP. In the current study, we tested the feasibility of using the
intrinsic fluorescence of a fragment of the ectodomain of APP
(residues 230–624), which contains both dimerization interfaces, to
identify molecules that can inhibit dimerization of the ectodomain
of APP. We show that two compounds with a similar quenching
effect on the intrinsic fluorescence bind to the same fragment of
APP and modify the proteolysis of intact APP to favor the
production of sAPPa. These results suggest that compounds that
inhibit the dimerization of the ectodomain of APP may increase
sAPPa production, thus providing a rationale for the development
of a new class of therapeutics for Alzheimer’s disease. Herein we
have identified two such compounds that bring about an increase
in sAPPa with a concomitant decrease in sAPPb through
inhibition of the dimerization of the ectodomain of APP.
Methods
Reagents
Dulbecco’s phosphate buffered saline (PBS) was purchased from
MediaTech. Disulfiram and Sulfiram were purchased from Tocris
Biosciences, 1-anilinonaphthalene-8-sulfonic acid (1,8-ANS) was
purchased from Invitrogen. ADAM10 was purchased from Sigma.
Reconstitution of the peptides and preparation of the
oligomers
All peptides were purchased from Anaspec. All of the work
reported herein was performed using one peptide lot. The
APP319-335 peptide and RERMS peptides were reconstituted
in PBS. The Ab peptides were reconstituted by adding 30 mlo f
100 mM sodium hydroxide to 0.5 mg of peptide. Once the
peptides were fully dissolved, PBS was added to bring the
concentration to 10–20 mM for Ab1-40 or Ab1-42. The more
soluble Ab fragments were diluted to 200 mM. The preparation of
the Ab oligomers is extensively described in Libeu et al (2011) [18]
which shows that this method produces three distinct size-ranges
of oligomers: 7-kDa dimers, a 13–20-kDa mixture of trimers to
hexamers and a 70-kDa population of primarily dodecamers. In
short, the aliquots of Ab1-40 or Ab1-42 were incubated at 37uC
for variable times and then characterized using a calibrated
Superdex 75 column with PBS as the running buffer. To reduce
the seeding effect and produce the 7-kDa Ab1-40 dimers and the
13-kDa Ab1-42 oligomers, the dissolved peptides were sonicated
for three pulses of 10 seconds using a Vibra Cell VCX130 (Sonics
and Material Inc.) with a 6 mm tip. The incubation times for the
7-kDa Ab1-40, 13-kDa Ab1-40 or 13-kDa Ab1-42, 70-kDa Ab1-
42 and 70-kDa Ab1-40 and .200-kDa Ab1-42 were 15 minutes,
30 minutes, 1 hour, 18 hours and 2 hours, respectively. To
fragment the .200-kDa Ab1-42 species, each 1 ml aliquot was
sonicated for three pulses of 4 seconds at 60% of maximum
amplitude. The aliquots were pooled and then divided again to
ensure uniformity between the aliquots. All of the size ranges of the
Ab oligomers were reproducible. However, the optimal incubation
times to produce each type of oligomer had to be determined
empirically each time the oligomers were prepared. Peptides were
frozen in aliquots of 1 ml at 220uC.
Effect on sAPPa and sAPPb production
B103 rat neuroblastoma cells and 7W-CHO cells were seeded at
100,000 or 50,000 cells per well in a 96-well plate and allowed to
grow for one day. The B103 rat neuroblastoma cells stably
expressing human wild-type APP were a kind gift from Dr.
Lennart Mucke (J. David Gladstone Institute of Neurological
Disease and University of California, San Francisco). The 7W-
CHO cells were a kind gift from Dr. Edward Koo (Department of
Molecular Pathology, University of California, San Diego). The
cell culture medium was then changed and the cells treated with
1 mM disulfiram, 1 mM sulfiram, or 0.01% DMSO (control). After
24 hours, the amount of sAPPa and sAPPb produced in the
medium was quantified using the AL231C and AL232C
AlphaLISA kits from Perkin Elmer, respectively, modified using
a custom biotinylated APP antibody.
Effect on ADAM10 cleavage in vitro
MBP-eAPP230–624 was incubated with 1 uM disulfiram for
15 minutes. Then, ADAM10 was added for 60 minutes. Time
points were taken every 20 minutes. The cleavage of MBP-
eAPP230–624 by the enzyme was quantified by the appearance of a
MBP-eAPP230–624 fragment detected by a sAPPa AlphaLISA
assay kit (Perkin Elmer, AL254C) using the PE Enspire reader.
Fluorescence studies
The thioredoxin fusion protein containing residues 290–624 of
APP695 (TRX-eAPP290–624), the maltose binding protein fusion
APP-Interacting Compounds Target APP Dimerization
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fragment of the APP containing residues 230–624 (eAPP230–624)
were expressed and purified as previously described [18]. The
absorption spectra of eAPP230–624 in the presence and absence of
disulfiram, sulfiram, and 1,8-ANS were measured with a
Spectramax 190 spectrophotometer (Molecular Devices) from
260 nm to 450 nm. The excitation spectra of the intrinsic
tryptophan fluorescence were recorded using either a Shimadzu
RF-530PC (Shimadzu Scientific Instruments) or a Spectramax
XPS spectrophotometer (Molecular Devices).
Full emission spectra were measured with the Shimadzu RF-
530PC using a 3 ml quartz cuvette, a 5 nm slit width and protein
concentrations between 0.2–0.6 mM. To minimize dilution effects,
titrations with 1,8-ANS, sulfiram, disulfiram, and the RERMS
peptide, were performed with concentrated compound so that the
final concentration was greater than 95% of the starting
concentration. Within this dilution range, control titrations with
protein and buffer indicated that the emission spectra scaled
linearly with protein concentration. For the Ab peptides, the
titrations were performed so that the final concentration was
greater than 75% of the starting concentration. For these larger
dilutions, control titrations with the protein alone were used to
generate a scaling matrix where the scale factor was both a
function of wavelength and dilution. Within the peak, the scale
factors for each wavelength were linear with respect to dilution. A
similar scaling matrix was used to correct for the effect of dilution
with DMSO. No significant changes in peak shape were observed
with up to 3% DMSO, although there was a modest increase in
the fluorescence intensity (,10%). All titrations were performed at
24uC. The oligomers were stored on ice during the experiment.
In addition to the titration experiments to control for possible
effects that the dilution may have had on the equilibrium of the Ab
oligomers, 47 mMA b oligomers were incubated with 7.8 mM
purified eAPP230–624 for 1 hour on ice before analysis. These
concentrations are analogous to concentrations used to create
complexes for the small angle x-ray scattering analysis. The
incubated material was diluted with PBS so that the final protein
concentration was 0.5 mM. The spectra were recorded with the
Shimadzu RF-503PC.
For experiments with the Spectromax XPS plate reader, an
excitation wavelength of 295 nm was used. This excitation
wavelength was chosen to minimize both the contribution of
tyrosine in the protein and the background fluorescence of the 96-
well plates (Costar #3915). The quenching experiments were
performed by diluting 20 ml of 0.5 mg/ml eAPP230–624 in 20 mM
Tris pH 7.4 with varying concentrations of 1,8-ANS in DPBS plus
2% DMSO or Ab oligomers in DPBS for a total volume of 190 ml.
As with the titration experiments, the Ab peptides did not exhibit
significant fluorescence when excited at 295 nm. To correct for
background, measurements were made of the various solutions in
the absence of the eAPP230–624. Since there was no significant
difference due to concentration in any of these solutions, the
measurements were averaged and then subtracted from the
measurements for the analogous protein-containing solutions.
The concentration ranges for the peptides or compounds were
chosen so that there were no apparent concentration-dependent
absorption effects as shown by lack of variation in the plate blanks.
For the quenching experiments, the data were analyzed by
constructing Stern-Volmer plots, F0/F vs. Q, where Fo is the
intensity of the fluorescence at zero concentration, F is the
intensity of the fluorescence, and Q is the concentration of the
quenching agent. When quenching is through either a static
(binding) or dynamic (collisional) mechanism this plot is linear and
follows the equation:
Fo=F~1zKsvQ ð1Þ
where Ksv is the quenching constant. When both processes are
present the Stern-Volmer plot is quadratic:
Fo=F~1z(KDzKS)QzKDKSQ2 ð2Þ
where KD is the equilibrium constant associated with dynamic
quenching and Ks is the equilibrium constant associated with static
quenching. All parameters were determined using PRISM
(GraphPad) and the appropriate non-linear curve fitting routine.
The centroid wavelength (lc) was calculated as:
lc~
P
i
I(li)li
P
i
li
ð3Þ
where I(li) is the intensity observed for the wavelength (li). The
range of wavelengths was 310–390 nm.
Small-angle X-ray scattering (SAXS)
Preparation of samples. For the Ab fragments, disulfiram,
and sulfiram incubated with MBP-eAPP230–624, 150 ml of protein
(<0.5 mg/ml) was diluted with 400 ml of peptide or compound
solution. The samples were incubated on ice for 20 minutes and
then concentrated to 50 ml with 10-kDa cutoff concentrators
(Millipore). All of the peptides and small molecules prepared in this
manner were less than 5-kDa in molecular weight. Samples of the
filtrates were used for buffer subtraction. To create a control for
the disulfiram and sulfiram experiments, which contained 2%
DMSO in the PBS, 400 ml of 2% DMSO in PBS was added to
150 ml of MBP-eAPP230–624 and then treated as the other samples.
For the other experiments, the appropriate eAPP fragment was
incubated on ice with either Ab oligomers or Ab fragments under
conditions where the peptide concentration was less than 10 mM.
The samples were then concentrated and purified with a Superdex
S200 size-exclusion column with 20 mM Tris pH 7.4, 100 mM
sodium chloride and 2 mM EDTA. Samples of the protein buffer
from the size-exclusion columns were used for buffer subtraction.
Previous experiments indicated that this method of preparation
resulted in Ab oligomer-eAPP230–624 complexes that were stable
for at least eighteen hours [18].
Data collection and processing. Small-angle X-ray scatter-
ing data were collected using protein concentrations in the range
of 0.5–3 mg/ml and an X-ray wavelength of 1.11 A ˚ at beam line
12.3.1 (Advanced Light Source). Data were integrated with
software customized for the beam line and processed with the
program PRIMUS [30]. The program GNOM [31] was used to
calculate the maximum dimension and the radius of gyration and
to estimate the intensity of the scattering at zero angle for higher
concentration samples. The dimensional data for each sample are
summarized in Table 1. Although dilutions of each sample were
analyzed to concentrations of approximately 0.3 mg/ml, no
significant differences were observed in the dimensional data
across the concentration ranges shown in Table 1.
Results
To explore the utility of using the intrinsic fluorescence of the
eAPP230–624 fragment to monitor binding of compounds, we first
characterized the intrinsic fluorescence of eAPP230–624, probed the
accessibility of the tryptophans to quenching by 1,8-ANS and then
APP-Interacting Compounds Target APP Dimerization
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intrinsic fluorescence. The conformational effects of the binding of
these ligands, different types of Ab oligomers and Ab fragments,
has been extensively characterized using SAXS [18]. Finally, we
used a combination of intrinsic fluorescence and SAXS to
determine whether molecules that alter the relative rates of a-
and b- cleavage of APP were ligands of eAPP230–624 and whether
their binding affects the dimerization of the APP ectodomain.
The eAPP230–624 fragment was chosen for these studies because
our previous study of the binding of Ab oligomers and Ab dimers
to the ectodomain of APP established that only residues 230–624
were required for these conformational changes induced by Ab-
binding [18]. Although the primary binding site of the Ab was
determined to be within the Ab-cognate region, significant
conformational changes occur in the dimer of the ectodomain of
APP (eAPP19–624) upon Ab binding. Binding of both Ab oligomers
and dimers was associated with unfolding of the acidic region
between the E1 (residues 19–210) and E2 (residues 290–540)
domains. Binding of Ab dimers also reduced the eAPP19–624
dimers to monomers, with a concomitant unfolding of residues
575–624 in addition to the acidic region. For both the Ab
oligomers and the Ab dimers, the E1 domain was not required for
either Ab binding or dimerization. The 230–624 fragment
contains only two tryptophans, W338 and W546 which simplifies
interpretation of its fluorescence. The SAXS model of the
homodimer of eAPP19–624 (Fig. 1A) predicts that the homodimer
of eAPP230–624 will have two populations of tryptophans: W338,
which should be partially solvent accessible on the surface of the
E2 domain, and W546, which should be located near the C-
terminal dimer interface [18]. Because of the low resolution of the
SAXS model, no predictions can be made about the accessibility
of W546.
Characterization of the intrinsic fluorescence of
eAPP230–624
eAPP230–624 has seven tyrosines, nine phenylalanines, and two
tryptophans. Although the fluorescence of tyrosine and phenylal-
anine are relatively insensitive to their environment, the fluores-
cence of tryptophan is highly sensitive to the environment. The
fluorescence peaks of tryptophans in proteins can be highly
variable, between 330 nm for tryptophans in less polar environ-
ments, such as buried within a protein, and 360 nm for
tryptophans in very polar environments [27]. Therefore, to obtain
the intrinsic fluorescence spectrum most sensitive to conforma-
tional changes, it is useful to minimize the fluorescence from the
tyrosines and phenylalanines. Using an excitation wavelength
greater than 290 nm minimizes the contribution of the tyrosines
and phenylalanines, since the excitation peaks of tyrosines and
phenylalanines are 274 and 260 nm, respectively [32]. This
principle is shown in practice for the 13-kDa Ab1-42 oligomers,
which lack tryptophan but have a modest intrinsic fluorescence
due to tyrosines and phenylalanines with an excitation wavelength
of 280 nm, but almost no intrinsic fluorescence at an excitation
wavelength of 295 nm (Fig. 1B).
The intrinsic fluorescence spectrum of eAPP230–624 has a peak
at 345 nm. This peak has the same peak shape as similar
concentrations of tryptophan in phosphate-buffered saline (PBS),
but is blue-shifted by 5 nm to 340 nm, indicating that both
tryptophans are likely to be partially accessible (Fig. 1B). Because
of the design of the Spectramax XPS plate reader, only
wavelengths in roughly the upper third of the intrinsic fluorescence
peak can be measured. The observed peak at 375 nm for
tryptophan and eAPP230–624 is created by the design of the
instrument since it is less sensitive near its emission cutoff of
360 nm (Fig. 1C).
Accessibility of the tryptophans in eAPP230–624 to
quenching by 1,8-ANS
Because the accessibility of W546 is unknown, 1,8-ANS was
used to probe the accessibility of the tryptophans in eAPP230–624.
1,8-ANS has been shown to bind to Ab oligomers and prevent Ab
aggregation [33,34]; therefore we reasoned that, since the Ab-
cognate region is involved in eAPP dimerization, 1,8-ANS might
also bind to the dimer of eAPP230–624 sufficiently near W546 to
Table 1. SAXS analysis of eAPP fragments and their
complexes.
Protein Peptide Dmax (A ˚)R g (A ˚)
MWcalc/
MWseq
TRX-eAPP290–624 -na- 150 41 2.0
TRX-eAPP290–624 Ab11-17 130 38 1.2
TRX-eAPP290–624 Ab 1-28 140 42 1.5
TRX-eAPP290–624 APP319-335 140 41 1.3
TRX-eAPP290–624 7-kDa Ab1-40 160 40 1.1
TRX-eAPP290–624 20-kDa Ab1-42 160 43 2.5
eAPP230–624 -na- 150 44 2.0
eAPP230–624 RERMS 130 39 1.8
eAPP230–624 Ab 1-28 170 46 0.9
eAPP230–624 7-kDa Ab1-40 180 49 1.2
eAPP230–624 20-kDa Ab1-42 170 46 2.6
MBP-eAPP230–624 -na- 190 55 2.0
MBP-eAPP230–624 2% DMSO 180 54 2.0
MBP-eAPP230–624 1,8-ANS 190 63 1.9
MBP-eAPP230–624 Sulfiram 170 53 1.7
MBP-eAPP230–624 Disulfiram 160 51 1.5
MBP-eAPP230–624 Ab10-20 160 51 1.3
MBP-eAPP230–624 Ab5-14 180 54 1.6
MBP-eAPP230–624 Ab12-24 180 54 1.8
MBP-eAPP230–624 Ab1-28 180 54 1.2
MBP-eAPP230–624 7-kDa Ab1-40 210 63 1.1
MBP-eAPP230–624 20-kDa Ab1-42 210 58 2.2
The maximum estimated error in the radius of gyration (R g)i s62A ˚.T h e
maximum estimated error in maximum dimension (Dmax)i s610 A ˚. Both values
were calculated with the program GNOM [31]. The relative mass was calculated
as the ratio of the apparent mass of the protein (MWcalc) to the expected mass
derived from the protein sequence (MWseq). The molecular weight derived from
the protein sequence is 52-kDa for TRX-eAPP290–624, 45-kDa for eAPP230–624,a n d
90-kDa for MBP-eAPP230–624. For globular, non-interacting proteins, the
apparent mass can be estimated by comparing the extrapolated scattering of
the sample at zero scattering angle (I(0)) to that of the reference protein
albumin and the eAPP fragment dimer
MWcalc~(CrefMrefIun(O))=(CunMunIref(O)),
where subscripts un and ref refer to the sample and the reference protein [56].
The error is the calculated mass is primarily due to the uncertainty in the
estimation of the concentrations. The maximum error was determined
experimentally by replicates of within a much larger set of experiments [18] to
be 60.2, where the maximum error determines the range of values for which
p,0.05. Monomeric proteins with 20–30% of their residues in random coil
conformation, as expected for monomeric APP, have relative mass estimates
around 1.3
51.
doi:10.1371/journal.pone.0040027.t001
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eAPP230–624 with 1,8-ANS had a significant effect on the
absorption of the eAPP230–624 protein at a one-to-ten molar ratio.
Binding of 1,8-ANS to the protein can be monitored by the
appearance of an absorption peak near 380 nm. 1,8-ANS bound
to protein absorbs in this region, while 1,8-ANS in solution does
not [35]. Changes in the absorption spectra can also reveal effects
on the environments of the tyrosines and tryptophans. In contrast
to phenylalanine, whose absorption is relatively insensitive to
environmental changes, the absorption of tyrosine and tryptophan
are both highly sensitive to the polarity of the environment [36].
These properties make the difference absorption spectra a useful
adjunct to the fluorescence studies for determining whether
quenching of the fluorescence is due to binding rather than
collisional processes. A compound that quenches the fluorescence
primarily by collisional processes will not display significant
changes in the difference absorption spectrum [32].
Binding of 1,8-ANS near tryptophans can quench tryptophan
fluorescence through Fo ¨rster energy resonance transfer (FRET).
Binding of 1,8-ANS to a protein requires positive charge donors to
counter the negative charge of the sulfonate group, but not
necessarily a large hydrophobic pocket [37]. As shown in Fig. 2B,
1,8-ANS efficiently quenched the intrinsic fluorescence due to the
tryptophans (excitation wavelengths greater than 285 nm) at a
1:20 protein to 1,8-ANS molar ratio. Figures 2C and 2D compare
the quenching observed with the Shimadzu RF-530PC (Fig. 2C)
and the Spectramax XPS plate reader (Fig. 2D). The calculated
quenching constants using the linear parts of the curves and
equation 1 are 9.360.1 mM
21 (345 nm) and 10.960.2 mM
21
(375 nm) for the Shimadzu RF-530PC and 9.660.3 mM
21
(375 nm) for the Spectramax XPS plate reader. At higher
concentrations, the Stern-Volmer plot for the quenching by 1,8-
ANS is quadratic, which suggests quenching by both binding and
collisional processes at high concentration (Fig. 2C). The upward
shift of the curve with temperature increase is consistent with
additional quenching of the intrinsic fluorescence by collisional
processes at higher concentrations. However, SAXS analysis
indicated a significant increase in the radius of gyration for the
MBP-eAPP230–624 dimer incubated with a 1:20 molar ratio of
protein to 1,8-ANS similar to that seen upon binding of Ab
oligomers, indicating that binding of 1,8-ANS induces a confor-
mational change in eAPP230–624 (Table 1). Therefore, conforma-
tional changes induced by increased 1,8-ANS binding may also
contribute to the shape of the curve. The significant quenching
below 50 mM (1:14 protein to 1,8-ANS molar ratio) is most likely
due to binding of the 1,8-ANS to the protein and the resulting
FRET with nearby tryptophans. Since the fluorescence intensity
drops by more than 50%, this suggests that at least two of the four
tryptophans in the dimer are close to the bound 1,8-ANS. This is
consistent with the hypothesis that the 1,8-ANS binds near the C-
terminal dimer interface which contains two of the tryptophans
Figure 1. The intrinsic fluorescence of eAPP230–624. A) Model of
the eAPP230–624 dimer derived from the SAXS model of eAPP19–624 [18]
illustrating the location of the tryptophans in eAPP230–624 with respect
to the dimerization interfaces. One monomer is shown in cyan and the
second monomer is shown in blue. The surface corresponding to W338
is colored red. The corresponding residue in the blue monomer is on
the back face, hidden in this view. The location of W546 and K624
cannot be precisely determined because of the low resolution of the
model (20 A ˚). The two residues are located within the volume encircled
by the dashed line. B) Emission peak of 0.64 mM eAPP230–624 in PBS
(black solid) and PBS containing 3.3% DMSO (black dotted) obtained
with an excitation wavelength (lex) of 295 nm using a Shimadzu RF-
530PC spectrophotometer with a 4 ml quartz cuvette. For comparison,
the spectra of 9 mM tryptophan in PBS (blue solid) and PBS-containing
3.3% DMSO (blue dotted) and 12 mMA b1-42 13-kDa oligomers in PBS
(purple) are shown. C) Emission peak of 3 mM eAPP230–624 in PBS
obtained with an excitation wavelength (lex) of 295 nm using a
Spectramax XPS spectrophotometer (black). For reference, the emission
spectra of 1–4 mM of tryptophan are also shown (grey). The peak shown
is created by the design of the instrument, which displays reduced
sensitivity as the wavelength approaches 360 nm.
doi:10.1371/journal.pone.0040027.g001
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e40027Figure 2. 1,8-ANS binds to eAPP230–624. A) Difference absorption spectra of eAPP230–624 in the presence of 1,8-ANS (purple) at a 1:10 molar ratio. For each
difference curve, the absorption spectra of PBS, PBS plus 1,8-ANS was subtracted from the absorption spectra of 3 mMe A P P 230–624 i nt h es a m eb u f f e r .T h e
appearance of significant changes in the peak absorption near 280 is consistent with perturbations in the environment of some of the aromatic residuesi n
eAPP230–624 caused by the binding of 1,8-ANS. The broad absorption peak centered on 380 nm is characteristic of 1,8-ANS bound to protein [55]. B)
Comparisonof the excitationpeakfor the intrinsic fluorescence at375 nmfor 3 mMeAPP 230–624alone(solid black) and in thepresenceof 1,8-ANSatmolar ratio
of1:20proteinto1,8-ANS at 375 nm(dotted purple) and500 nm (purple). This comparisonshows that thepresence of 1,8-ANS at a 1:20 molar ratiois sufficient
to redirect the absorbed photons in the region dominated by tryptophan absorption (285–300 nm) into emission peak of 1,8-ANS at 500 nm consistent with
FRET between the tryptophans and bound 1,8-ANS molecules. C) Emission spectra of the titration of 0.64 mMe A P P 230–624 with 1,8-ANS from 0–120 mM (1:0–
1:180 molar ratio) using the Shimadzu RF-530PC. The black line indicates the starting concentration and the purple line indicates the final concentration. D)
Stern-Volmer plot for intermolecular quenching of the intrinsic fluorescence of eAPP230–624 by 1,8-ANS at 24uC derived from titration data from the Shimadzu
RF-530PC. E) Emission spectrum of 4 mMe A P P 230–624 in PBS with varying molar ratios of 1,8-ANS from 1:0 (black) to 1:55 (purple) obtained using the
Spectramax XPS. F) Stern-Volmer plot for intermolecular quenching of the intrinsic fluorescence of eAPP230–624 by 1,8-ANS at 24uC( p u r p l e )a n d4 2 uC( r e d )a s
measured on the Spectramax XPS. The protein concentration was 2 mM for E–F.
doi:10.1371/journal.pone.0040027.g002
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e40027Figure 3. Ab-binding to eAPP230–624 can be measured using intrinsic fluorescence. A) Size-exclusion chromatography analysis of Ab
oligomer preparations using a Superdex 75 column and PBS as the running buffer. As an example, 13-kDa Ab1-42 (red) and 7-kDa Ab1-40 (gold) are
shown. B) Emission spectra of the titration of 0.64 mM eAPP230–624 with 13-kDa Ab1-42 from 0–13 mM (1:0–1:27 molar ratio) using rapid dilution and
the Shimadzu RF-530PC. The aliquots were 100 ml each diluted into a starting volume of 3 mls. The black line indicates the starting concentration and
the red line indicates the final concentration. The pink line indicates a molar ratio of 1:12 protein to Ab oligomers. The arrow indicates the direction of
shift of the fluorescence peak. C) Emission spectra of the 0.5 mM eAPP230–624 incubated with a 1:6 (grey) and 1:12 (red) molar ratio of 13-kDa Ab1-42
oligomers. The emission spectrum of eAPP230–624 alone is shown in black. D) Emission spectra of 0.5 mM eAPP230–624 with Ab species greater than
200-kDa before sonication (dark blue) and after sonication (light blue). The inset compares the chromatogram of 0.1 mgA b species before (dark blue)
and after sonication (light blue) using a calibrated Superdex 75 column with PBS as the running buffer. Before sonication, the Ab oligomers do not
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e40027and the Ab-cognate regions known to bind 1,8-ANS. The fact that
a sufficiently high concentration of 1,8-ANS (greater than
150 mM) can quench nearly all the fluorescence indicates that all
four tryptophans are solvent accessible.
Effect of Ab binding on the intrinsic fluorescence of
eAPP230–624
To characterize the effect of the binding of Ab oligomers on the
intrinsic fluorescence of eAPP230–624, pools of Ab oligomers of
varying sizes were generated and classified by the size of the
dominant oligomer using a calibrated Superdex-75 or Superdex-
200 size-exclusion column, as described in Libeu et al (2011) [18].
Fig. 3A shows the results of the preparation of 13-kDa Ab1-42 and
7-kDa Ab1-40. Previous cross-linking analysis demonstrated that
these peaks contain predominately trimers and dimers, respec-
tively [18,38]. Titration using rapid dilution with 13-kDa Ab-42
oligomers to a final 1:27 molar ratio dramatically shifted the
emission peak from 345 to 338 nm, the centroid wavelength from
350 to 346 nm, and increased the intensity of the fluorescence by
114%. This pattern in the change of fluorescence is consistent with
a decrease in the accessibility of one or more tryptophans (Fig. 3B).
However, the pattern of change in the intrinsic fluorescence is
highly similar to the change observed for titration with Ab1-40
dimers (Fig. 4A). The similarity suggests that the changes in the
intrinsic fluorescence might be induced by binding of Ab1-42
dimers or monomers rather than oligomers. Several effects may
contribute to this observation. Oligomerization of larger Ab
oligomers has been reported to be reversible by dilution at similar
concentrations [39]. Ab1-42 dimers are known to be in
equilibrium with Ab1-42 trimers [38]. Finally, the sheering forces
induced by the constant stirring may retard the formation of larger
oligomers or cause larger oligomers to break-up.
To determine whether the order of dilution was important, the
same 13-kDa Ab1-42 oligomers were incubated with eAPP230–624
on ice prior to dilution. As shown in Fig. 3C, the pattern of the
change in the fluorescence with increasing oligomer concentration
was strikingly different. At the 1:12 molar ratio, the fluorescence
intensity was 82% of eAPP230–624 alone; while for the rapid
dilution, the fluorescence intensity was 108% of eAPP230–624
alone. The shift in the peak wavelengths and the centroid
wavelengths is similar between the two methods, from 345 nm to
343 nm for the peak wavelength and from 350 nm to 348 nm for
the centroid wavelength. Since the total protein and Ab
concentrations are similar between the two experiments, the
difference is not driven by final concentrations or non-specific
solvating effects due to the presence of the Ab. Analysis with small
angle x-ray scattering (SAXS) of the complexes formed during
incubation of eAPP230–624 or MBP-eAPP230–624 with similar-sized
Ab1-42 oligomers disclosed a molecular mass consistent with the
binding of an approximately 25–30-kDa Ab1-42 oligomer to a
dimer of the protein. This observation suggests that the
fluorescence spectra obtained from incubating the protein with
the oligomers prior to dilution corresponds to the binding of the
25–30-kDa Ab1-42 oligomer to eAPP230–624 and that the large
decrease in fluorescence intensity after incubation is due to
quenching of one of the tryptophans as a consequence of this
binding.
As we have reported previously [18], the apparent size of the
oligomer that binds to the eAPP fragments is independent of the
size of the oligomers incubated with the fragment as long as the
oligomer preparations contain oligomers between 13-kDa and 70-
kDa and A-11 positive oligomers are present. This observation
suggests that during the incubation a remodeling process occurs
that produces oligomers of the particular size that preferentially
bind to eAPP. To determine whether the remodeling process
could be detected by intrinsic fluorescence, we incubated the
eAPP230–624 with Ab oligomers with different characteristic sizes.
As shown in Fig. 3D, incubation of eAPP230–624 with Ab1-42
species greater than 200-kDa in size at a 1:6 molar ratio gave a
relatively minor change in the fluorescence spectra consistent with
the poor ability of the larger species to make complexes with the
eAPP230–624 observed previously. Sonication of these large Ab
species broke them into smaller, more soluble oligomers (Fig. 3D
inset). Incubation of eAPP230–624 with the sonicated Ab1-42
material produced a decrease in the fluorescence intensity to 87%
that of eAPP230–624 and a 1 nm blue-shift in the centroid
wavelength, from 250 nm to 249 nm. Similar modest shifts were
observed with the incubations with 70-kDa Ab1-40 and 70-kDa
Ab1-42 at the 1:6 molar ratio (Fig. 3E). Like the 13-kDa Ab1-42
(Fig. 3C), 13-kDa Ab1-40 decreased the intensity to 80%, however
it did not produce a significant blue shift.
Although the Shimadzu RF-503PC gives the most information
about the tryptophan environments, monitoring the binding at
higher molar ratios is limited by the large amount of oligomeric
Ab required to record high-quality spectra. As shown with the
comparison between the two instruments for quenching with 1,8-
ANS, the Spectramax XPS gives relatively little information on the
peak shape, but it can be used to monitor binding with a 30-fold
lower investment of Ab oligomers because of the symmetrical
nature of the peaks. We found that studies could be done using
concentrations of Ab up to 120 mM in which all the replicates can
be measured at the same time within 15 minutes of setup. These
characteristics are highly advantageous for the higher concentra-
tions of Ab, which continue to aggregate at 24uC, enhancing
reproducibility of the measurements. As shown in Fig. 3F,
increasing the molar ratio with either the Ab1-42 or Ab1-40
oligomers from Fig. 3E resulted in further quenching of the
fluorescence at 375 nm, presumably due to similar shifts in the
fluorescence peak shape to those shown in Fig. 3C. The efficiency
of the quenching by the Ab oligomers depended on the size of the
oligomers. The largest Ab-species (greater than 200-kDa) gave a
slight enhancement of the intrinsic fluorescence similar to the
curves shown for the Ab fragments in Fig. 4D. The half-maximum
point of each curve is close to the 1:20 molar ratio which was
shown to be effective at inducing conformational changes in the
ectodomain of APP [18]. The similarity supports the conclusion
that co-incubation of Ab oligomers with eAPP230–624 promotes a
remodeling process that results in the preferred approximately 30-
kDa size for binding to the ectodomain of APP. The sigmoidal
shape of the titration curves for the oligomers suggested a
cooperative binding process. Fitting of the curves using the
enter the column. E) Emission spectra of the 0.5 mM eAPP230–624 incubated with a 1:6 molar ratio of 13-kDa Ab1-40 (lavender), 13-kDa Ab1-42 (red),
70-kDa Ab1-40 (green) and 70-kDa Ab1-42 (purple). The spectra of the 70-kDa Ab1-40 and Ab1-42 are nearly completely superimposed, so that only
the 70-kDa Ab1-40 is visible F) Changes in the intrinsic fluorescence of eAPP230–624 resulting from incubation of with the same Ab oligomers from D
and E:13-kDa Ab1-40 (black with lavender center), 70-kDa Ab1-40 (green), 70-kDa Ab1-42 (purple), .200-kDa Ab1-42. The dominant sizes of the Ab
oligomers were determined by size-exclusion chromatography. None of the oligomers were purified, so the size represents only the major species in
the mixture. The excitation wavelength was 295 nm for all spectra and the data were measured using the Spectramax XPS.
doi:10.1371/journal.pone.0040027.g003
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equation
Fo=F~1:0z(A{1:0)=(1z(EC50{x)^n)) ð4Þ
where F0 is the fluorescence at zero concentration, x is the molar
ratio of Ab oligomers to eAPP230–624, n is the number of Ab
molecules bound, A is a parameter related to the maximum
response of the intrinsic fluorescence, and EC50 is the molar ratio
that invokes half the response. For the Ab oligomers less than 70-
kDa in size, constraining n to 7 maximized the fit for all three
curves in Fig. 1C (R
2=0.88 for all three curves). The log(EC50)s
were 1.2760.02, 1.3260.01, and 1.2960.01 for 13-kDa Ab1-40,
70-kDa Ab1-40, and 70-kDa Ab1-42, respectively. The average of
these EC50 values corresponds to a molar ratio of approximately
1:20 eAPP230–624 to Ab. None of the log(EC50)s were significantly
different at the p,0.05 confidence level, indicating that these
different Ab oligomer preparations varied only in the amplitude of
the maximal response (A). This amplitude most likely varies
because each pool of oligomers varies in its ability to remodel and
produce eAPP-binding oligomers. Although we do not understand
the remodeling process, the ratio of the amplitudes suggests that
the 13-kDa Ab1-40 can produce about 150% more oligomers that
can bind eAPP, which is consistent with the conclusion of the
earlier SAXS studies that demonstrated that the pools with smaller
oligomers (<20-kDa) were more efficient at binding the ectodo-
main than pools with larger oligomers (<70-kDa) [18]. A value of
seven for n is in surprisingly good agreement with the number of
molecules bound to the eAPP fragments as estimated by SAXS.
The molecular weight, as estimated by SAXS, clusters between
25–30-kDa for the different experiments (Table 1), while the mass
of an Ab1-42 heptamer is 30-kDa.
In contrast to the Ab oligomer pools, titration of eAPP230–624
with Ab1-40 dimers (Fig. 4A) or fragments of Ab resulted in a
small but significant enhancement of the intrinsic fluorescence to
110–115% and blue shifts in the centroid wavelength between
0.5–1.5 nm. For comparison, calculation of the expected error in
the centroid wavelength from the average spectra and repeated
independent measurements of the eAPP230–624 spectra both gave a
variation in the centroid wavelength of 60.2 nm. No significant
differences were observed between the results for the titration
protocol and the incubation protocol for the Ab1-40 dimers (not
shown). The fragments shown in Fig. 4C, Ab1-28, Ab12-28, and
Ab10-20 acted like Ab1-40 dimers in terms of the changes in the
intrinsic fluorescence, except for the shortest peptide (Ab10-20),
which caused a 5 nm red-shift at the peak and a 2 nm blue shift in
the centroid wavelength, indicating a significant distortion of the
shape of the intrinsic fluorescence peak (Fig. 4B). The change in
the normalized fluorescence for each peptide was highly similar,
clustering about the same line. This uniformity is consistent with
the observation that all of these peptides induce monomerization
of the eAPP ectodomain and result in a similar highly flexible
eAPP monomer [18]. The changes in the fluorescence spectra are
Figure 4. Binding of Ab fragments to eAPP230–624 can be
measured using intrinsic fluorescence. A) Emission spectra from
the titration of 0.64 mM eAPP230–624 with 7-kDa Ab 1-40 from 0–13 mM
(1:0–1:20 molar ratio) using the Shimadzu RF-530PC. The black line
indicates the starting concentration and the gold line indicates the final
concentration. The arrow indicates the direction of shift of the
fluorescence peak. B) Emission spectra from the titration of 0.64 mM
eAPP230–624 with Ab 10–20 from 0–46 mM (1:0–1:70 molar ratio) using
the Shimadzu RF-530PC. The black line indicates the starting
concentration and the blue line indicates the final concentration. The
arrow indicates the direction of shift of the fluorescence peak. C)
Summary of the results of titrating 0.64 mM eAPP230–624 with various
fragments of Ab that inhibit eAPP dimerization: Ab1-40 (black circles),
Ab1-28 (black diamonds), Ab12-28 (black triangles), Ab 10–20 (black
squares), Ab12-24 (yellow squares), Ab5-14 (yellow diamonds) and
Ab16-20 (yellow circles) from 0–60 mM (1:0–1:85 molar ratio depending
on the fragment). The excitation wavelength is 295 nm and the
emission wavelength is 345 nm. To exclude the possibility that Ab1-28
or Ab10-20 formed oligomers, samples of these peptides were analyzed
using size-exclusion chromatography as shown in Fig. 3A. Both of these
peptides eluted 0.5 mls later than the 7-kDa peak, indicating that they
are smaller dimers or monomers.
doi:10.1371/journal.pone.0040027.g004
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dimers and fragments being associated with monomerization of
the protein (Table 1). All of the fragments that monomerized
eAPP230–624 also have a strong binding affinity for Ab oligomers
and some activity in reducing the rate of fibrillization [40]. This
correlation suggests that these peptides bind directly to the Ab-
cognate region, remote from W338. Therefore, the expected shift
for the tryptophans would be an increase in the solvation of W546
due to disruption of the dimerization interface near the Ab-
cognate region, which is consistent with the modest changes
observed in the fluorescence spectra. The larger changes in the
fluorescence spectra observed for Ab10-20 suggest the complex
has a different conformation than the complex with the other
peptides, or, alternatively, the Ab10-20 may interact directly with
one of the tryptophans. SAXS analysis of this complex indicated
that the monomer produced was significantly smaller than that
produced with the larger peptides, with a maximum dimension of
160 A ˚ and a radius of gyration of 51 A ˚, in contrast to the 7-kDa
Ab-40 complex, which had a maximum dimension of 210 A ˚ and a
radius of gyration of 63 A ˚.
Our data indicate that there is a distinct pattern of change in the
intrinsic fluorescence induced by Ab oligomers (which stabilize the
eAPP homodimer) vs. Ab fragments and dimers (which mono-
merize the eAPP homodimer). This difference is consistent with
the conclusions from the previous SAXS analysis that the final
conformation of the ectodomain in each complex is very different
from the native conformation of the dimer, as is the conformation
of the heteromultimeric ectodomain-Ab oligomer complex from
the ectodomain-Ab dimer complex.
Both the Ab oligomers and the 1,8-ANS demonstrate that
compounds that bind near the C-terminal dimer interface may
generate a large signal in the intrinsic fluorescence. These results
indicate that the intrinsic fluorescence of the eAPP230–624 dimer
may be used to monitor binding of small molecules to eAPP230–624
near the C-terminal dimer interface of the ectodomain of APP.
Figure 5. Interaction of RERMS peptides with eAPP. A) Emission spectra from the titration of 0.64 mM eAPP230–624 with RERMS peptides from
0–270 mM (1:0–1:420 molar ratio) using the Shimadzu RF-530PC. The black line indicates the starting concentration and the red line indicates the final
concentration. The arrow indicates the direction of shift of the fluorescence peak. B) Stern-Volmer plot for the intermolecular quenching of 0.64 mM
eAPP230–624 by the RERMS peptide for the emission wavelengths: 345 nm (purple diamonds) and 375 nm (black circles) C) Model of APP319-335
peptide bound to the E2 domain of APP derived from a dimer of an E2 domain fragment (residues 299 to 490) observed in its crystal structure protein
data base entry 1RW6 [25]. The major interactions between the peptide and the protein are two hydrogen bonds involving Arg 328 and both polar
and hydrophobic interactions between Met 335 and the hydrophobic pocket. The rim of the hydrophobic pocket into which Met 335 binds is 9 A ˚
from the C-terminus of the E2 domain fragment. D) Superposition of the peptide model (pink) with the SAXS model. The green balls show the
predicted path in the SAXS model of the chain that forms a bridge from the terminus of the E2 domain to the dimer interface containing the C-
terminus of eAPP230–624. The overlap of the surfaces shows the overlap between the peptide docked into its binding site and the predicted path of
the eAPP230–624 residues indicating that the two models are incompatible. This overlap suggests a mechanism by which binding of an RERMS peptide
in the binding site predicted by the crystal structure could influence the stability of the dimer of eAPP230–624.
doi:10.1371/journal.pone.0040027.g005
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balance of a- and b- cleavage
Of particular interest is the identification of compounds that can
alter the balance between a- and b- cleavage of APP, but do not
affect the processing enzymes directly. A 17-amino acid peptide
(APP319–335) that contains the RERMS sequence is an example
of such a compound. This peptide is sufficient to stimulate growth
of fibroblasts in an APP-independent manner [41] and enhances
the production of sAPPa in neuronal cells [42]. The RERMS
peptide itself (APP 328–332) has a similar activity, albeit with a 10-
fold reduced potency. The mechanism by which the RERMS
peptide enhances the production of sAPPa is unknown, although
evidence suggests that the RERMS peptide binds to cell surface
receptors.
One of these receptors may be APP, since SAXS analysis of the
complex of the peptide APP319–335 with the TRX-eAPP290–624
construct confirmed that the longer peptide competes with
dimerization of the TRX-eAPP290–624 fragment (Table 1), just as
Ab1-40 dimers and Ab fragments do. As shown in Fig. 5A, the
RERMS sequence quenches the intensity of the intrinsic
fluorescence with an approximately 2 nm red-shift in the peak
position and a 1 nm red-shift in the centroid wavelength. The
change in shape of the peak with increasing concentrations of
peptide can be seen in the smaller rate of change in the
fluorescence at 375 nm than near the peak (345 nm) (Fig. 5B).
Analysis of the complex of eAPP230–624 with RERMS by SAXS
indicates that the complex is a dimer with a significantly smaller
maximum dimension and radius of gyration than the native dimer.
The likely binding site of the RERMS peptide is not the Ab-
cognate region. In the crystal structure of the E2 domain, the
RERMS sequence contributes to the formation of an E2-dimer,
indicating a binding site in the E2 domain for this sequence
(Fig. 5C). Superposition of this particular dimer found in the
crystal structure with the dimer model derived from SAXS [18]
suggests residues 319–335 from one of the subunits of the dimer
from the crystal structure occupy the same space as the residues
that lead to the C-terminal dimerization interface in the SAXS
model (Fig. 5D). The conflict between these two models suggests
that binding of RERMS-containing peptides such as APP319–335
in this location could modulate the dimerization of the APP
ectodomain by altering the stability of the C-terminal dimerization
interface. The shorter peptide (RERMS) is less likely to interfere
with the dimerization because of its greater flexibility. The
positioning of these peptides is consistent with the observation
that the longer peptide forms a monomer complex, while the
shorter peptide forms a more compact dimer.
Our second example emerged from a previous screen of a
clinical library for compounds that alter the balance of a- and b-
cleavage of APP: the compounds disulfiram (Antabuse, used to
treat chronic alchoholism) and sulfiram (Temosol, an ectopar-
Figure 6. Disulfiram and Sulfiram increase sAPPa production.
A) Effect of treatment with disulfiram and sulfiram on sAPPa and Ab
production in 7W-CHO cells. 7W-CHO cells were seeded at 50,000 cells
per well in a 96-well plate and allowed to grow for one day. The cell
culture medium was then changed and the cells treated with 1 mM
disulfiram, 1 mM sulfiram, or 0.01% DMSO (control). After 24 hours, the
amount of sAPPa and sAPPb produced in the medium was quantified
using the AL231C and AL232C AlphaLISA kit from Perkin Elmer,
modified using a custom biotinylated human APP antibody. B) Effect on
the ratio of a to b cleavage in 7W-CHO cells, as calculated by dividing
the amount of sAPPa to sAPPb produced by the 50,000 7W-CHO cells
during one day under the effect of either disulfiram, sulfiram or a DMSO
control. C) Effect on the ratio of a to b cleavage in B103 cells. B103
neuroblastoma cells were seeded at 100,000 cells per well in a 96-well
plate and allowed to grow for one day. The cell culture medium was
then changed and the cells treated with 1 mM disulfiram, 1 mM sulfiram,
or 0.01% DMSO (Control). After 24 hours, the amount of sAPPa and
sAPPb produced in the medium was quantified using the same
modified AL231C and AL232C AlphaLISA kit from Perkin Elmer. The ratio
of a to b cleavage was calculated by dividing the amount of sAPPa to
sAPPb produced by the 100,000 B103 cells during one day under the
effect of the disulfiram, sulfiram or DMSO control.
doi:10.1371/journal.pone.0040027.g006
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cleavage significantly in 7W CHO (Fig. 6A and 6B) and B103
(Fig. 6C) cells transfected with APP. Addition of disulfiram or
sulfiram to eAPP230–624 resulted in a significant drop in the
extinction coefficient (Fig. 7A). This change was not due to
aggregation of the protein caused by the addition of the DMSO.
Analysis by size-exclusion chromatography indicated no significant
changes in the elution time of the native dimer of eAPP230–624 in
the presence of 2% DMSO at the concentrations used for the
difference absorption and fluorescence studies (#0.5 mg/ml) (not
shown), nor was there a significant change in the size of the protein
in the SAXS analysis (Table 1). Both disulfiram and sulfiram
significantly quenched the intrinsic fluorescence (Fig. 7B and 7C).
In addition, disulfiram significantly distorted the peak shape,
shifting the fluorescence peak from 344 nm to 357 nm, indicating
that at least one of the tryptophans is fully hydrated. Both the
difference absorption spectrum and the fluorescence are consistent
with a significant conformation change on binding of the
disulfiram or the sulfiram to eAPP230–624. The Stern-Volmer plot
for disulfiram has a slope 1.6 times greater than the slope for
sulfiram (Fig. 7D) indicating that disulfiram has a higher binding
affinity for eAPP230–624 than sulfiram.
To determine whether binding of sulfiram or disulfiram caused
significant conformational changes in the MBP-eAPP230–624,w e
examined the conformation of eAPP230–624 in the presence of a
12-fold molar excess of sulfiram or disulfiram by small angle x-ray
scattering. The MBP-eAPP230–624 fusion protein was used for the
SAXS analysis because both TRX-eAPP290–624 and eAPP230–624
tended to precipitate upon addition of 1–2% DMSO at the
concentrations required for the analysis (.1.5 mg/ml). The
presence of both sulfiram and disulfiram significantly affected
the monomer-dimer equilibrium of MBP-eAPP230–624 in favor of
the monomer, as evidenced by the decrease in apparent molecular
weight (Fig. 8A). Consistent with the interpretation that disulfiram
binding favors the MBP-eAPP230–624 monomer; the maximum
dimension and radius of the disulfiram-treated MBP-eAPP230–624
were significantly smaller than the dimer of MBP-eAPP230–624
(Table 1). This monomer has a different conformation than the
monomer induced by binding of the Ab1-40 dimers, since the
latter have a larger radius of gyration and maximum dimension
than the MBP-eAPP230–624 dimers due to uncoiling of the acidic
region between the two domains. The weaker effect of sulfiram in
the SAXS analysis, intrinsic fluorescence, and difference absorp-
Figure 7. Disulfiram and Sulfiram bind to eAPP230–624. A) Difference absorption spectra of eAPP230–624 in the presence of sulfiram (blue) and
disulfiram (dotted red) at a 1:6 molar ratio. For each difference curve, the absorption spectra of PBS +2% DMSO, PBS plus 2% DMSO and 50 mM
sulfiram or PBS plus 2% DMSO and 50 mM disulfiram were subtracted from the absorption spectra of 8.3 mM eAPP230–624 in the same buffer. B)
Emission spectra from the titration of 0.64 mM eAPP230–624 with disulfiram from 0–130 mM (1:0–1:202 molar ratio) using the Shimadzu RF-530PC. The
black line indicates the starting concentration and the red line indicates the final concentration. The arrow indicates the direction of shift of the
fluorescence peak. C) Emission spectra from the titration of 0.64 mM eAPP230–624 with sulfiram from 0–320 mM (1:0–1:500 molar ratio) using the
Shimadzu RF-530PC. The black line indicates the starting concentration and the blue line indicates the final concentration. The arrow indicates the
direction of shift of the fluorescence peak. E) Stern-Volmer plot for the intermolecular quenching of 0.64 mM eAPP230–624 with either disulfiram
(346 nm –red circles and 375 nm red diamonds) or sulfiram (346 nm–blue circles and 375 nm-blue diamonds).
doi:10.1371/journal.pone.0040027.g007
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sAPPa production in cells.
To confirm that disulfiram binding disrupts the dimer interface
of the fusion protein and changes the accessibility of the a-cleavage
site to proteolysis, MBP-eAPP230–624 was probed using ADAM10,
a physiologically relevant alpha-secretase candidate protease
involved in the production of sAPPa [43]. As shown in Fig. 8B,
treatment with disulfiram did in fact increase the accessibility of
the a-cleavage site near lysine 612 to ADAM10 cleavage.
Discussion
Our data confirm that intrinsic fluorescence of the eAPP230–624
fragment is useful as a tool in the discovery of compounds or
peptides that inhibit the dimerization of eAPP230–624 or alter the
conformation of the dimer. Although it is difficult to interpret the
spectra in terms of specific conformational changes because the
dimer of eAPP230–624 contains four tryptophans, the fluorescence
of those tryptophans is highly responsive to binding of Ab
oligomers or fragments to eAPP230–624, which induce large enough
conformational changes to be detected by small angle x-ray
scattering. In addition, the examples of the RERMS-containing
peptides, disulfiram, and sulfiram, suggest that intrinsic fluores-
cence can be used to identify non-Ab-based compounds that
inhibit the dimerization of eAPP230–624 or alter the conformation
of the dimer. These limited examples suggest that this APP
conformation modulation property correlates with the ability of
such compounds to influence the ratio of a- vs. b-cleavage of APP
in cells. Our data suggest that these compounds may be analogous
to a series of compounds that bind the APP dimerization interface
within the transmembrane domain, the GXXXG motif, and have
been shown to be c-site modulators [44]. The mechanism by
which sulfiram, disulfiram, and the RERMS-containing peptides
are effective in increasing the a-cleavage of APP remains to be
determined. We hypothesize that the activity of sulfiram and
disulfiram is due to their ability to destabilize intermolecular
interactions in the full-length APP dimer near the Ab-cognate
region and to alter the accessibility of the a-, b-cleavage sites to
proteases. Because a-cleavage occurs primarily on the cell surface
[45], compounds with this type of APP conformation modulation
activity as measured by changes in the tryptophan fluorescence
should favor a-cleavage over b-cleavage. Increasing the accessi-
bility of the a-cleavage site on the cell surface is only one possible
mechanism. b-cleavage is also thought to be more efficient for
dimeric than monomeric APP [46], so that compounds interfering
with dimerization of eAPP230–624 by altering the conformation
near the BACE site could also alter the ratio of a-, b-cleavage.
Finally, the compounds could induce conformational changes that
alter APP’s ability to form heterodimers or heparin-mediated
homodimers. APP has been shown to interact with a number of
different cell surface proteins, and some of these compete with Ab
for binding to APP. For example, competition between exoge-
nously added Ab1-42, which rapidly aggregates into larger
oligomers, and the common neurotrophin receptor p75
NTR, for
APP binding, has been demonstrated in cell culture [47]. The
large conformational change associated with oligomeric Ab
binding suggests a mechanism by which oligomeric Ab binding
could compete with other ligands, by precluding conformations of
the ectodomain favorable to their binding. This type of
competition may have a significant impact on both the signaling
and processing of APP, since the ectodomain of APP has been
implicated in forming heterodimers and higher order complexes
with a number of other ligands and receptors such as Netrin-1
[13], ApoE [48,49], Notch [50,51], p75
NTR [47], APLP1, APLP2
[52], BRI2 [53], and BRI3 [54]. For all of these proteins,
interaction with APP occurs through a region containing the Ab-
cognate sequence, which forms part of one of the dimerization
interfaces of eAPP230–624. Although the functions of the British
dementia proteins, BRI2 and BRI3, are unknown, the other
proteins have been implicated in signal transduction complexes
Figure 8. Disulfiram inhibits dimerization of MBP-eAPP230–624.
A) Small angle x-ray scattering analysis of MBP-eAPP230–624 incubated
with 50 mM disulfiram or 50 mM sulfiram at a 1:12 molar ratio in PBS plus
2% DMSO. Incubation with either disulfiram or sulfiram produces
significant deviations in the scattering curves indicating a significant
shift in size and shape. The Guinier plot of MBP-eAPP230–624 (black),
sulfiram-treated (blue), and disulfiram-treated (red) is shown in the
inset. The y-axis of the Guinier plot is normalized so that one unit is
proportional to 90-kDa (the molecular mass of MBP-eAPP230–624). The
molecular mass of the complex can be obtained from the extrapolated
y-intercept of the best-fit line. The downward shift of the line indicates
that both sulfiram and disulfiram shift the monomer-dimer equilibrium
in favor of the monomer. The curvature of the Guinier plot for disulfiram
is evidence that the sample is a mixture of monomer and dimer. B)
Cleavage of MBP-eAPP230–624 with ADAM10 as measured by AlphaLisa.
doi:10.1371/journal.pone.0040027.g008
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PLoS ONE | www.plosone.org 13 June 2012 | Volume 7 | Issue 6 | e40027that regulate the balance of neurite outgrowth vs. retraction.
Compounds that bind to the ectodomain of APP near this region
and influence the conformation of the residues surrounding the
Ab-cognate region could influence both homo- and heterodimer-
ization, and thereby change the rate of APP turnover or
proteolysis.
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